Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

NCT01029340 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Blood Coagulation Disorders
Hemophilia A

Interventions

BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)
BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)
BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)

Sponsor

Bayer